In FTD, TMEM106b Fibrils Tip TDP-43 Dysfunction into Overdrive
Risk variant promotes TMEM106b fibrillization; protective variant discourages it.
6412 RESULTS
Sort By:
Risk variant promotes TMEM106b fibrillization; protective variant discourages it.
A panel of experts concludes the evidence for this scary prospect is weak, but recommends neurosurgeons use separate neurosurgical instruments for young and old patients. The experts called for further studies.
In a comparison with aducanumab and gantenerumab, lecanemab mopped up protofibrils most efficiently; the antibody has been chosen for DIAN-TU and AHEAD 3-45 trials.
The α-helical chains of two ApoEs wrap around lipoprotein discs. They circle in opposite directions.
Among 1,092 people with PCA, symptoms started around age 60, and 94 percent had amyloid plaques or neurofibrillary tangles.
Scientists worry about trial recruitment and retention, and discuss whether upcoming trials should allow aducanumab as a background therapy.
Two men with loss-of-function variants in their APOE4 alleles escaped amyloid pathology. One was in his 90s.
With several thousand people across the U.S. on the drug, wait times are long, and clinics are hiring. How to meet growing demand?
The patient, an APOE4 homozygote with severe cerebral amyloid angiopathy, developed vascular inflammation and bleeding throughout her brain.
Growth-associated protein 43 in the CSF identified people who accumulated tangles fastest. These spread through connected brain regions.
Scientists around the globe are studying how best to deploy Alzheimer's plasma tests in the real world. Their focus: primary care.
A Rand report concludes that using blood-based biomarkers and cognitive tests in primary care would halve wait times for new disease-modifying therapies.
The software could improve prognosis, speed referrals, for people with MCI, the developer claims.
Using live imaging in mice, scientists found that tracers and immune cells move between brain and dura through gaps in the arachnoid mater around veins.
With newly available fluid biomarkers that detect α-synuclein pathology in the brain, researchers articulate ways to classify the disease based on its biology.
No filters selected